{"data":{"issuanceinfo":{"industrycode":"204005","industry":"醫療保健","ipoprice":{"ceiling":"24.000","floor":"20.300"},"ipodate":{"start":"2020-09-23 00:00:00","end":"2020-09-28 00:00:00"},"minimumcapital":"12120.92","subscribed":"1247.52","marketcap":"115.46億","H_marketcap":"--","pe":"--","codesrate":"3.00","link":"https://staticpdf.iqdii.com/stockdata/notice/06998/2020/2020092300016_c.pdf","ipopricing":"24.000","resultdate":"2020-10-06 00:00:00","enddate":"2020-09-28 00:00:00","listeddate":"2020-10-07 00:00:00","issuenumber":"11988.10萬","issuenumberhK":"5994.10萬","issuenumberother":"5994.00萬","grayprice":"31.60","sponsors":"高盛(亞洲)有限責任公司,摩根大通證券(遠東)有限公司,富瑞金融集團香港有限公司","raisemoney":"269370.00萬","use":"1、所得款項凈額的42%，或約1,131.4百萬港元，用于為我們核心產品的研發活動提供資金；\n2、所得款項凈額的23%，或約619.6百萬港元，用于為我們其他主要產品的研發活動提供資金；\n3、所得款項凈額的15%或約404.1百萬港元，用于撥付我們管線中其他候選藥物正在進行及計劃進行的臨床試驗、適應癥擴展及注冊備案籌備；\n4、所得款項凈額的10%或約269.4百萬港元，用于為我們的藥物管線擴展提供資金；\n5、所得款項凈額的10%或約269.4百萬港元作一般企業用途。","shares":500,"leadagent":"高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,富瑞金融集團香港有限公司,招銀國際融資有限公司,華興證券(香港)有限公司,海通國際證券有限公司,麥格理資本股份有限公司","bookrunners":"高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,富瑞金融集團香港有限公司,招銀國際融資有限公司,華興證券(香港)有限公司,海通國際證券有限公司,麥格理資本股份有限公司","coordinator":"高盛(亞洲)有限責任公司,摩根大通證券(亞太)有限公司,富瑞金融集團香港有限公司","firstDayOpen":"29.20","IsEiio":0,"Interestdays":8,"PENote":"按經審核的最近年度公司股東應占溢利和發行后總股本計算；發行價未確定時，按招股價中間價計算；發行價確定后，按招股定價計算。","OverAllotment":"有","StabilizingManager":"高盛(亞洲)有限責任公司","code":"E06998","name":"嘉和生物－Ｂ","fullname":"嘉和生物藥業(開曼)控股有限公司"},"institutioninfo":{"principaloffice":"中國上海浦東新區張衡路1690號3號樓","registrars":"香港中央證券登記有限公司","registrarstel":"(852) 2862 8628","chairman":"易清清","secretary":"蕭穎潔","telephone":"(8621) 6169 0700","substantialshareholders":"高瓴(29.38%),康和醫療及康嘉醫療(12.01%),沃嘉(7.81%),Aranda Investments及TG River(6.73%)","principalactivities":"公司為一間正在進入商業化階段的生物制藥公司，專注于腫瘤及自身免疫藥物的研發及商業化。","website":"http://www.genorbio.com"},"managerinfo":[{"managername":"易清清","post":"董事會主席兼非執行董事","rankno":1},{"managername":"周新華","post":"總裁、首席科學家兼執行董事","rankno":2},{"managername":"郭峰","post":"首席執行官兼執行董事","rankno":3}],"investorinfo":[{"institutionname":"HHJH Holdings Limited","shareholding":"11,219,000.0","percentage":9.36,"ReleaseDate":"2021-04-07 00:00:00","relatedparty":"Hillhouse Capital","subsidiary":["Gaoling Fund, L.P.","Hillhouse Funds","Gaoling Yali Fund, L.P.","HHJH Holdings Limited"],"InverstorType":"基金"},{"institutionname":"OrbiMed Funds","shareholding":"8,013,500.0","percentage":6.68,"ReleaseDate":"2021-04-07 00:00:00","relatedparty":"OrbiMed Capital LLC","subsidiary":["OrbiMed Funds","Worldwide Healthcare Trust PLC"],"InverstorType":"基金"},{"institutionname":"香港泰格健康科技有限公司","shareholding":"7,052,500.0","percentage":5.88,"ReleaseDate":"2021-04-07 00:00:00","relatedparty":"杭州泰格醫藥科技股份有限公司","subsidiary":["香港泰格健康科技有限公司"],"InverstorType":"公司"},{"institutionname":"太平洋資產管理有限責任公司","shareholding":"6,411,000.0","percentage":5.35,"ReleaseDate":"2021-04-07 00:00:00","relatedparty":"中國太平洋保險(集團)股份有限公司","subsidiary":["太平洋資產管理有限責任公司","長江養老保險股份有限公司"],"InverstorType":"公司"}],"TotalShareholdingPercentage":50},"result":1,"Version":"4.5.190802.46408","ElapsedMilliseconds":10}